November - 2012
| Previous Next | Showing Journal 2 of 23 |
Associations Between Aldosterone Antagonist Therapy and Risks of Mortality and Readmission Among Patients With Heart Failure and Reduced Ejection FractionAdrian F. Hernandez, Xiaojuan Mi, Bradley G. Hammill, et al. JAMA, 2012, 308(20):2097-2107 This page is only available to Crit-IQ subscribers. To view the rest of this review and gain access to our vast array of critical care teaching tools including podcasts, vodcasts, modules, exam preparation tools, teaching aids and much more, login here, or Become a Member to register |
November |
Previous Comments
No Comments yet.
Comment
This observational trial examines translation of the clear evidence of benefit from, aldosterone antagonists in heart failure with reduced EF (HFREF), into safety and efficacy in clinical practice. The authors were particularly interested in older, sicker, minority group patients who...